EUVIMEDEUVIMED entdecken
LeserbriefOpen Access

Letter to the Editor: A Favorable Benefit–Risk Balance Maybe Expected with Replication-Defective Adenovirus-Mediated Interferon Gene Therapy for Cancer Treatment

Albert Qin iD

Human Gene Therapy · 2023

DOI: 10.1089/hum.2023.028 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Human Gene Therapy, 2023. Verfasst von Albert Qin. Beteiligte Einrichtung: Medical Research and Clinical Operations, PharmaEssentia Corporation, Taipei, Taiwan. Hauptthemen laut MEDLINE: Adenoviridae, Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 4 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenoviridaeNeoplasmsInterferonsGenetic TherapyGenetic VectorsImmunotherapyVirus Replication

Substanzen

Interferons

Autor:innen und Institutionen

  • Medical Research and Clinical Operations, PharmaEssentia Corporation, Taipei, Taiwan.

ORCID-Profile: Albert Qin

Zitieren

APA

Qin, A. (2023). Letter to the Editor: A Favorable Benefit–Risk Balance Maybe Expected with Replication-Defective Adenovirus-Mediated Interferon Gene Therapy for Cancer Treatment. Human Gene Therapy. https://doi.org/10.1089/hum.2023.028

Vancouver

Qin A. Letter to the Editor: A Favorable Benefit–Risk Balance Maybe Expected with Replication-Defective Adenovirus-Mediated Interferon Gene Therapy for Cancer Treatment. Human Gene Therapy. 2023. doi:10.1089/hum.2023.028

BibTeX
@article{Qin2023,
  author = {Qin, Albert},
  title = {Letter to the Editor: A Favorable Benefit–Risk Balance Maybe Expected with Replication-Defective Adenovirus-Mediated Interferon Gene Therapy for Cancer Treatment},
  journal = {Human Gene Therapy},
  year = {2023},
  doi = {10.1089/hum.2023.028}
}
Kostenlos starten →